Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments

Area of Science:

• Pediatric Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Neuroblastoma is a frequent pediatric extracranial solid tumor, often diagnosed at metastatic stages.
• Metastatic neuroblastoma carries a poor prognosis due to high rates of refractory or recurrent disease.
• Nuclear medicine, particularly meta-iodobenzylguanidine ([¹²³I]mIBG) imaging, is crucial for staging and response assessment.

Purpose of the Study:

• To review current and emerging nuclear medicine imaging tracers for neuroblastoma.
• To evaluate the characteristics, diagnostic accuracy, and limitations of these tracers.
• To highlight the advantages of advanced imaging techniques for optimizing treatment strategies.

Main Methods:

• Review of current literature on nuclear medicine imaging in neuroblastoma.
• Analysis of established tracers like [¹²³I]mIBG scintigraphy and SPECT-CT.
• Evaluation of novel positron emission tomography (PET) tracers including [¹²⁴I]mIBG, [¹⁸F]mFBG, [¹⁸F]FDG, [⁶⁸Ga]Ga-DOTA peptides, [¹⁸F]F-DOPA, and [¹¹C]mHED.

Main Results:

• [¹²³I]mIBG imaging is standard but has limitations, with 10% of neuroblastomas being non-avid and lower sensitivity for small lesions.
• PET imaging offers superior spatial resolution and whole-body tomographic capabilities compared to SPECT.
• New PET tracers demonstrate potential for improved sensitivity and accuracy in detecting neuroblastoma extent.

Conclusions:

• Advanced nuclear medicine imaging, especially PET, is needed to overcome limitations of [¹²³I]mIBG for precise neuroblastoma staging.
• Emerging PET tracers offer enhanced diagnostic accuracy for optimizing treatment strategies in pediatric neuroblastoma.
• Continued research into novel radiotracers is essential for improving outcomes in high-risk neuroblastoma patients.